ongoing

The overall goal of Liraglutide for patients receiving Endovascular Stroke Thrombectomy (LEAST) is to test whether subcutaneous (SC) liraglutide can improve the functional outcomes of adults with acute ischemic stroke attributed to an intracranial large vessel occlusion (LVO) who are planned for treatment with endovascular thrombectomy (EVT). This vanguard trial will obtain the factual feasibility prerequisites essential for the planning, design, funding and execution of a subsequent main phase trial.

LEAST is a multicentre, vanguard, prospective, open-label, blinded endpoint (PROBE) trial. LEAST will recruit a total of 100 adult patients scheduled to receive EVT at approximately 10 high-volume stroke research centres in Canada over 12 months. Participants fulfilling the inclusion and exclusion criteria will be randomly assigned up to 4 hours from the end of the EVT procedure, defined as the time of the last angiographic run, to either receive liraglutide (0.6 mg SC daily for 1 week followed by 1.2 mg SC daily for another 12 weeks) or to no liraglutide treatment.

The primary feasibility endpoint is recruitment rate. Secondary feasibility endpoints include retention rates and medication adherence.

Study Type

Pilot study

Study Design

Multicentre, phase II, pilot RCT

NO. of Countries

1

NO. of Sites

10

NO. of Participants

100

Study Period

2025-2027

Sponsor

PHRI

Canadian Institutes of Health Research (CIHR)

Back To Top